ArticlePulmonary medicine2016
The Protective Effect of Naringin against Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats.
Article in Pulmonary medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 74 citations in OpenAlex.
- Current perspectives on natural and pharmacological interventions for combating drug-induced pulmonary toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Naringin nanoparticles alleviate RA-ILD pulmonary fibrosis by targeting 14-3-3ζ to inhibit LYVE1Materials today. Bio · 2026Article
- The protective effects of naringin against cisplatin-induced pulmonary toxicity in rats: Insights into the modulation of ER stress and SIRT1/Nrf2 pathway.BMC complementary medicine and therapies · 2026Article
- Cardioprotective, anti-inflammatory, and antioxidative outcome of costus against bleomycin-induced cardiotoxicity in rat model.Journal, genetic engineering & biotechnology · 2025Article
- HMGB1 Box A gene therapy to alleviate bleomycin-induced pulmonary fibrosis in rats.BMC pulmonary medicine · 2025Article
- Effects of Natural Products through Inhibiting Endoplasmic Reticulum Stress on Attenuation of Idiopathic Pulmonary Fibrosis.Drug design, development and therapy · 2024Review
- Natural plant resource flavonoids as potential therapeutic drugs for pulmonary fibrosis.Heliyon · 2023Review
- Betulin-rich hydroalcoholic extract ofHeliyon · 2023Article
- Naringin regulates endoplasmic reticulum stress and mitophagy through the ATF3/PINK1 signaling axis to alleviate pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- TMT proteomics analysis reveals the mechanism of bleomycin-induced pulmonary fibrosis and effects of Ginseng honeysuckle superfine powdered tea.Chinese medicine · 2023Article
- Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications.Pharmaceutics · 2023Review
- Meleagrin Isolated from the Red Sea FungusBiomedicines · 2022Article
- Current update on the protective effect of naringin in inflammatory lung diseases.EXCLI journal · 2022Article
- Aerosol Delivery of Surfactant Liposomes for Management of Pulmonary Fibrosis: An Approach Supporting Pulmonary Mechanics.Pharmaceutics · 2021Article
- Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.Biomolecules · 2020Review
- Zingerone ameliorates oxidative stress and inflammation in bleomycin-induced pulmonary fibrosis: modulation of the expression of TGF-β1 and iNOS.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Modeling radiation-induced lung injury: lessons learned from whole thorax irradiation.International journal of radiation biology · 2020Review
- Wedelolactone Attenuates Pulmonary Fibrosis Partly Through Activating AMPK and Regulating Raf-MAPKs Signaling Pathway.Frontiers in pharmacology · 2019Article
- Recurrent DNA damage is associated with persistent injury in progressive radiation-induced pulmonary fibrosis.International journal of radiation biology · 2018Article
- Combination ofChinese medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the current study was to investigate the protective effect of naringin on bleomycin-induced pulmonary fibrosis in rats. Twenty-four Wistar rats randomly divided into four groups (control, bleomycin alone, bleomycin + naringin 40, and bleomycin + naringin 80) were used. Rats were administered a single dose of bleomycin (5 mg/kg; via the tracheal cannula) alone or followed by either naringin 40 mg/kg (orally) or naringin 80 mg/kg (orally) or water (1 mL, orally) for 14 days. Rats and lung tissue were weighed to determine the lung index. TNF-α and IL-1β levels, hydroxyproline content, and malondialdehyde (MDA) levels were assayed. Glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities were determined. Tissue sections were stained with hematoxylin-eosin, Masson's trichrome, and 0.1% toluidine blue. TNF-α, IL-1β, and MDA levels and hydroxyproline content significantly increased (p < 0.01) and GPx and SOD activities significantly decreased in bleomycin group (p < 0.01). Naringin at a dose of 80 mg/kg body weight significantly decreased TNF-α and IL-1β activity, hydroxyproline content, and MDA level (p < 0.01) and increased GPx and SOD activities (p < 0.05). Histological evidence supported the results. These results show that naringin has the potential of reducing the toxic effects of bleomycin and may provide supportive therapy for conventional treatment methods for idiopathic pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.